Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lexaria Bioscience's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $6.52 Mil. Lexaria Bioscience's Total Assets for the quarter that ended in Feb. 2024 was $6.35 Mil.
Therefore, Lexaria Bioscience's Equity to Asset Ratio for the quarter that ended in Feb. 2024 was 1.03.
The historical rank and industry rank for Lexaria Bioscience's Equity-to-Asset or its related term are showing as below:
LEXX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37 Med: 0.96 Max: 1.08
Current: 1.03
During the past 13 years, the highest Equity to Asset Ratio of Lexaria Bioscience was 1.08. The lowest was 0.37. And the median was 0.96.
LEXX's Equity-to-Asset is ranked better than 99.74% of 1563
companies
in the Biotechnology industry
Industry Median: 0.66
vs LEXX: 1.03
Lexaria Bioscience Equity-to-Asset Historical Data
The historical data trend for Lexaria Bioscience's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's Equity-to-Asset
For the Biotechnology subindustry, Lexaria Bioscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Equity-to-Asset falls into.
Lexaria Bioscience Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lexaria Bioscience's Equity to Asset Ratio for the fiscal year that ended in Aug. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lexaria Bioscience Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience (Lexaria Bioscience) Business Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 